The ?real-world? clinical efficacy of ranibizumab has been demonstrated in a recently published study in the journal Clinical Ophthalmology.
The 'real-world' clinical efficacy of ranibizumab has been demonstrated in a recently published study in the journal Clinical Ophthalmology.
Led by Dr Jean-Marie Rakic (Centre Hospitalier Universitaire de Liège, Belgium), the team examined the treatment patterns of ranibizumab and the quality of life outcomes over a 2-year period in both real-world and clinical settings. A total of 267 patients suffering from wet age-related macular degeneration (AMD) were treated with 0.5 mg intravitreal injections of ranibizumab in this prospective, observational, multicentre, open-label study. Visual acuity, visual function, quality of life and safety were all assessed during follow up.
It was found that visual acuity improved to a statistically significant level from baseline by 2.5 months and these improvements were maintained to 6 months. However, this improvement was not statistically significant at 12 months and there was a decline from baseline by 24 months.
The majority of patients, however, were found to have improved or stable disease at the final time point and the visual function and quality of life scores were also improved and maintained at 24 months in just over a third of the study group.
Based on these results, the team summarized that the real-world clinical efficacy of ranibizumab was demonstrated. Additionally, the results highlighted the necessity of individualized treatment regimes to ensure optimal visual and quality of life outcomes.
For more detailed information please view the abstract here.